** Shares of drug developer Sionna Therapeutics SION.O set to open 33% above their offer price in their Nasdaq debut
** Stock indicated to open at $24 vs $18 IPO price
** SION sold ~10.6 mln shares, 20% more than initially offered, at the top end of its marketed range of $16 to $18 apiece to raise $190.6 mln
** At the IPO price, the Waltham, Massachusetts-based firm fetched a valuation of $765.4 mln
** Founded in 2019 and previously known as Sling Therapeutics, SION is developing drugs to treat cystic fibrosis
** SION is vying for a slice of the cystic fibrosis market that is dominated by drugmaker Vertex Pharmaceuticals VRTX.O
** Vertex booked almost $10 billion in sales in 2023 and has significantly impacted cystic fibrosis treatment
** Prior to the IPO, SION had raised about $330 mln from investors, including RA Capital, TPG's The Rise Fund, Atlas Venture, OrbiMed and Enavate Sciences
** Goldman Sachs, TD Cowen, Stifel and Guggenheim Securities were the underwriters
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.